Stage 4 stomach cancer means the cancer has spread from the stomach to distant parts of the body. It is the most advanced stage, and regardless of how far the tumor has grown into the stomach wall or whether nearby lymph nodes are involved, the defining feature is that cancer cells have reached other organs. The five-year relative survival rate for distant stomach cancer is about 8%, based on data from the National Cancer Institute’s SEER program covering 2016 to 2022.
What Makes It Stage 4
Stomach cancer staging follows a system based on three factors: how deeply the tumor has grown into the stomach wall (T), whether it has reached nearby lymph nodes (N), and whether it has spread to distant sites (M). Stage 4 is defined by M1, meaning distant metastasis is present. The T and N values can be anything. A tumor that barely penetrates the stomach lining but has seeded the liver is still stage 4, while a tumor that has invaded the entire stomach wall with extensive lymph node involvement but no distant spread is stage 3.
Where Stomach Cancer Typically Spreads
A study of nearly 4,750 patients diagnosed with metastatic stomach cancer in the United States found clear patterns. The peritoneum, the thin membrane lining the abdominal cavity, was the most common site, affected in 43% of patients. The liver was next at 26%, followed by distant lymph nodes in 20% of cases. Bone, brain, and lung metastases together accounted for about 11%.
Peritoneal spread is particularly common in stomach cancer because the stomach sits directly within the abdominal cavity. Cancer cells can shed from the stomach’s outer surface and implant on nearby organs or the peritoneal lining itself. This type of spread is also one of the hardest to detect on standard imaging. CT and PET-CT scans have low sensitivity for small peritoneal deposits, which is why doctors sometimes perform a staging laparoscopy, a minimally invasive procedure where a small camera is inserted through the abdomen to look for cancer that imaging missed.
Symptoms of Advanced Stomach Cancer
Early stomach cancer often causes vague symptoms that overlap with common digestive issues. By stage 4, symptoms tend to be more pronounced and may relate both to the stomach tumor itself and to the sites where cancer has spread.
One of the most recognizable complications is ascites, an abnormal buildup of fluid in the abdomen. This happens when cancer cells spread to the peritoneum and cause it to leak excess fluid. Ascites can cause visible abdominal swelling, bloating, a feeling of tightness, unexplained weight gain (from the fluid), shortness of breath, and nausea. Appetite loss, fatigue, and swelling in the ankles or legs often accompany it.
Cachexia, a syndrome of severe weight loss and muscle wasting, is another hallmark of advanced stomach cancer. It goes beyond simply not eating enough. The cancer itself drives metabolic changes that break down muscle and fat, making it difficult to maintain body weight even with adequate calories. Many patients also experience pain in the abdomen or back, difficulty swallowing, vomiting (sometimes with blood), and dark or tarry stools from internal bleeding.
How It’s Treated
Treatment for stage 4 stomach cancer is palliative, meaning the goal is to slow the cancer’s growth, relieve symptoms, and extend life rather than achieve a cure. The specific approach depends heavily on the molecular characteristics of the tumor, which are determined through biopsy testing.
One key test looks for a protein called HER2 on the surface of cancer cells. About 15% of people with advanced stomach cancer have HER2-positive tumors. For these patients, initial treatment typically combines chemotherapy with a drug that targets HER2 directly. If the tumor also shows elevated levels of another protein called PD-L1 (measured by a scoring system called CPS), an immunotherapy drug may be added to the combination. In clinical trials, this triple approach reduced the risk of death by roughly 30% in patients with high PD-L1 levels compared to chemotherapy alone.
For the majority of patients whose tumors are HER2-negative, treatment usually starts with chemotherapy combined with immunotherapy. In large trials, adding immunotherapy to chemotherapy reduced the risk of death by about 22% overall, with greater benefit in patients whose tumors expressed higher levels of PD-L1. For HER2-negative cancers, immunotherapy can be used regardless of PD-L1 level, though the benefit appears strongest when PD-L1 is elevated.
If the first treatment stops working, several second-line options exist. These include different chemotherapy drugs, a targeted drug that blocks blood vessel growth to the tumor, and for certain molecular subtypes, additional immunotherapy options. Doctors test tumors for specific genetic features, such as problems with DNA repair mechanisms or a high number of mutations, to identify which patients are most likely to respond.
When Surgery Still Has a Role
Surgery is not a standard treatment for stage 4 stomach cancer because the disease has already spread beyond what can be removed. However, palliative surgery is sometimes performed to manage specific complications. If a tumor is blocking the passage of food through the stomach, surgery can relieve the obstruction. If the tumor is causing significant bleeding, an operation can help control it. These procedures are not intended to remove all cancer but to improve quality of life and prevent dangerous emergencies.
Nutritional Challenges and Support
Maintaining nutrition is one of the most difficult aspects of living with advanced stomach cancer. The tumor itself can interfere with eating by causing nausea, early fullness, or obstruction. Cachexia compounds the problem by altering the body’s metabolism so that calories are burned inefficiently.
Clinical guidelines recommend working with a registered dietitian who can provide practical advice on high-protein, high-calorie, nutrient-dense foods tailored to what the patient can tolerate. Importantly, guidelines from the American Society of Clinical Oncology advise against routinely using feeding tubes or intravenous nutrition (parenteral nutrition) for cachexia in advanced cancer. These interventions do not reverse the metabolic changes driving muscle loss and can introduce complications. A short-term trial of parenteral nutrition may be considered in select situations, such as when a bowel obstruction is potentially reversible, but this is the exception rather than the rule.
Factors That Influence Outlook
The 8% five-year survival figure represents an average across all patients with distant stomach cancer, but individual outcomes vary. Several factors shift the prognosis in either direction. Tumor biology matters significantly: patients whose cancers respond to targeted therapy or immunotherapy often live longer than the average suggests. Performance status, a measure of how well a person can carry out daily activities, is one of the strongest predictors. Patients who are relatively active and able to tolerate treatment tend to fare better than those who are already significantly weakened at diagnosis.
The location and extent of metastases also play a role. A patient with a single small liver metastasis faces a different situation than someone with widespread peritoneal disease and ascites. Roughly 35% of all stomach cancers are already at the distant stage when first diagnosed, which reflects how often the disease progresses silently before symptoms become impossible to ignore.